Your browser doesn't support javascript.
loading
Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination.
Collier, Ai-Ris Y; McMahan, Katherine; Jacob-Dolan, Catherine; Liu, Jinyan; Borducchi, Erica N; Moss, Bernard; Barouch, Dan H.
Afiliación
  • Collier AY; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • McMahan K; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Jacob-Dolan C; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Liu J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Borducchi EN; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Moss B; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Barouch DH; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
medRxiv ; 2024 Sep 11.
Article en En | MEDLINE | ID: mdl-39314978
ABSTRACT
The replication-incompetent modified vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN; Jynneos) was deployed during the 2022 clade IIb mpox outbreak. On August 14, 2024, the World Health Organization declared the mpox clade Ib outbreak in the Democratic Republic of the Congo a public health emergency of international concern, which has raised the question about the durability of vaccine immunity after MVA-BN vaccination. In this study, we show that the MVA-BN vaccine generated mpox serum antibody responses that largely waned after 6-12 months.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...